Developments in the treatment of advanced-stage hepatocellular carcinoma include novel locoregional interventions aiming to induce tumour necrosis and systemic treatments targeting the biological mechanisms of tumour progression, thus aiming to delay progression. These approaches fiercely battle to provide the best survival, but their lack of success to date suggests that they might be better tested as a complementary approach.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Forner, A., Reig, M. & Bruix, J. Hepatocellular carcinoma. Lancet 391, 1301–1314 (2018).
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163–1173 (2018).
Yoon, S. M. et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy versus sorafenib in hepatocellular carcinoma with macroscopic vascular invasion. JAMA Oncol. 4, 661–669 (2018).
Galle, P. R. et al. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908–943 (2018).
Huang, L. et al. Correlation between overall survival (OS) and time to progression (TTP) and between OS and response rate (RR) by RECIST in advanced hepatocellular carcinoma (HCC). Ann. Oncol. https://doi.org/10.1093/annonc/mdx369.086 (2017).
Reig, M. et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology 58, 2023–2031 (2013).
Vilgrain, V. et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 18, 1624–1636 (2017).
Chow, P. K. H. et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J. Clin. Oncol. https://doi.org/10.1200/JCO.2017.76.0892 (2018).
Ricke, Sangro, B. et al. The impact of combining selective internal radiation therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the Soramic trial palliative cohort. J. Hepatol. 68, S65–S104 (2018).
Acknowledgements
J.B. gratefully acknowledges grant support from Instituto de Salud Carlos III (PI14/00962), Asociación Española Contra el Cáncer (AECC; PI044031), Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2014 SGR 605), and Worldwide Cancer Research (WCR; formerly known as AICR) 16–0026. CIBER of Hepatic and Digestive Diseases (CIBERehd) is funded by the Instituto de Salud Carlos III.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.B. had acted as a consultant of Abbvie, Arqule, Bayer, Boehringer Ingelheim, BMS, BTG, Eisai, Gilead, Kowa, Novartis, Onxeo, OSI, Roche, Sirtex, and Terumo and has a research contract with Bayer. M.S.Z. declares no competing interests.
Rights and permissions
About this article
Cite this article
Sanduzzi-Zamparelli, M., Bruix, J. Locoregional versus systemic therapy — robust positive data remain elusive. Nat Rev Clin Oncol 15, 537–538 (2018). https://doi.org/10.1038/s41571-018-0047-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0047-6
